FRANCISCO JAVIER
SALMERÓN ESCOBAR
Investigador en el periodo 2002-2020
Hospital General Universitario de Valencia
Valencia, EspañaPublicaciones en colaboración con investigadores/as de Hospital General Universitario de Valencia (25)
2021
-
Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects
Liver International, Vol. 41, Núm. 9, pp. 2076-2086
2020
-
Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure
Antiviral Research, Vol. 174
-
Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis
Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 1, pp. 216-225.e5
-
Erratum to: “Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25) (Journal of Hepatology (2020) 73(1) (17–25), (S0168827820301276), (10.1016/j.jhep.2020.02.028))
Journal of Hepatology
-
Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH
Journal of Hepatology, Vol. 73, Núm. 1, pp. 17-25
2019
-
Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH
Gastroenterologia y Hepatologia, Vol. 42, Núm. 10, pp. 657-676
-
Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort
Journal of Viral Hepatitis, Vol. 26, Núm. 1, pp. 55-64
-
Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild-moderate fibrosis: Results from a real-world cohort
Liver International, Vol. 39, Núm. 1, pp. 90-97
-
High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world
Journal of Hepatology, Vol. 71, Núm. 5, pp. 876-888
-
Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort
PLoS ONE, Vol. 14, Núm. 8
2018
-
Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline
Gastroenterologia y Hepatologia, Vol. 41, Núm. 5, pp. 328-349
-
Erratum to «Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline» [Gastroenterol Hepatol. 2018;41(5):328-349] (S0210570518300037) (10.1016/j.gastrohep.2017.12.003))
Gastroenterologia y Hepatologia
2015
-
Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis
World Journal of Gastroenterology, Vol. 21, Núm. 30, pp. 9163-9174
-
Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection
Genes and Immunity, Vol. 16, Núm. 5, pp. 297-300
2011
-
Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin
American Journal of Gastroenterology, Vol. 106, Núm. 7, pp. 1246-1254
2008
-
Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C
Journal of Hepatology, Vol. 48, Núm. 5, pp. 721-727
-
Hospital admission is a relevant source of hepatitis C virus acquisition in Spain
Journal of Hepatology, Vol. 48, Núm. 1, pp. 20-27
-
Optical analysis of computed tomography images of the liver predicts fibrosis stage and distribution in chronic hepatitis C
Hepatology, Vol. 47, Núm. 3, pp. 810-816
-
Quasispecies as predictive factor of rapid, early and sustained virological responses in chronic hepatitis C, genotype 1, treated with peginterferon-ribavirin
Journal of Clinical Virology, Vol. 41, Núm. 4, pp. 264-269
2007
-
Induction doses of interferon-α-2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non-responders to interferon monotherapy: A randomized trial
Journal of Viral Hepatitis, Vol. 14, Núm. 2, pp. 89-95